Today: August 24, 2017, 8:55 am
  
Health

New Report Available: Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022

Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs
New Report Available: Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022
PR-Inside.com: 2017-05-19 17:05:12
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years. Disease progression results in stiffness and pain, especially in the hands and feet, which hinders mobility. Without treatment, the disease leads to joint destruction and disability.

The chronic nature of the disease, which requires ongoing treatment, and the relatively high annual cost of therapy (ACoT) have made RA treatment a highly lucrative market.

The RA therapeutic market has become very competitive due to the high number of new drug approvals. Competition is fierce, particularly among TNF-a inhibitors, which dominate the treatment market for RA patients who are refractory to traditional disease-modifying anti-rheumatic drugs (DMARD). Despite this, 30% of RA patients fail to attain a clinical response when treated with TNF-a inhibitors. However, other targeted programs, as well as newly marketed small-molecule DMARDs such as the Janus kinase (JAK) inhibitor Xeljanz (tofacitinib), have the potential to replace ineffective TNF-a inhibitors. Recently published study results of Xeljanz have shown a significant reduction in the risk of developing cardiac diseases such as heart attack and stroke in patients with RA.


Full Report Details at
- www.fastmr.com/prod/1279328_rheumatoid_arthritis.aspx?afid=701

Despite the superior efficacy of recently marketed therapies over traditional DMARD therapies, there is a need to improve safety in the therapeutic landscape. Elevated rates of infection are a frequent consequence of the immunosuppression involved in treatments, but this is required to suppress the autoimmune responses responsible for the symptoms of the condition. As a result, these biological therapies are not recommended to patients who are susceptible to infection.

In addition, there is a need to create biologics with more convenient and less invasive drug-delivery methods, as all existing therapies are administered subcutaneously or intravenously. These routes of administration are frequently associated with pain, rash, and allergic reactions at the injection or infusion site, and in the case of infusion flu-like illness, fever, chills, nausea, and headache. Therefore convenient and safe administration without significant compromise of therapy efficacy remains an unmet need.

Although the recently approved drug Xeljanz is an orally administered small-molecule drug, indicated as a second-line treatment for RA patients who have not shown an adequate response to methotrexate, and as a third-line therapy for patients who have not responded sufficiently to biologics, it carries a black-box warning in the US due to the safety issues of serious infections and malignancy.

Report Scope

The current South-East Asia RA market contains novel products, including Xeljanz, a JAK inhibitor; and Actemra (tocilizumab), an IL-6 receptor inhibitor.

- What are the competitive advantages of the existing novel drugs?

There are over 450 active pipeline molecules, and most of the late-stage investigational drug candidates feature improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.

- Which classes of novel drugs are most prominent in the pipeline?

- What is the potential for pipeline products to address unmet needs in the RA market?

Analysis of clinical trials since 2006 identified that the failure rates of RA molecules were highest in Phase II, at 72.6%, with the overall attrition rate for RA standing at 94.6%.

- How do failure rates vary by stage of development, molecule type, and molecular target?

- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?

Over the 2015-2022 forecast period, the South-East Asia RA therapeutics market is expected to increase in value at a CAGR of 4.7%, from $1.04 billion to over $1.4 billion.

- Which markets make the most significant contribution to the current market size?

- What are the epidemiology trends in these markets?

- Will new market entrants lead to substantial changes in annual therapy costs?

- How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?

Rising RA prevalence population and the uptake of newer therapies will lead to significant market growth over the forecast period, despite the launch of biosimilars of blockbuster anti-TNFs.

- Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?

Reasons to Get this Report

This report will enable you to -

About GBI Research

GBI Research provides industry-leading global business intelligence solutions. Their products and services help companies make better business decisions, win business and position themselves more effectively. GBI Research publishes more than 100 research reports each year across a wide range of industries. These reports draw on in-depth primary and secondary research, databases of proprietary in-house data and high quality analysis from their expert teams. GBI Research employs hundreds of highly qualified Analysts across the US, Europe and Asia. View more research from GBI Research at www.fastmr.com/catalog/publishers.aspx?pubid=1016&afid=701

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

Press Information


Published by
Bill Thompson
18008448156
e-mail
www.fastmr.com



# 897 Words
Related Articles
More From The Author
New Market Research Report: Mexico Endoscopy Fluid [..]
GlobalData's new report, "Mexico Endoscopy Fluid Management Systems Market Outlook to 2023", provides key market data [..]
Report Published: "Eosinophilic Esophagitis - Pipeline [..]
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Pipeline Review, [..]
New market study, "Global Smart Backpack Market [..]
Smart backpacks are a new generation of luggage that features some advanced technological enhancements such as embedded sensors, [..]
Now Available: Crohn's Disease (Regional Enteritis) - [..]
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease (Regional Enteritis) - [..]
Fluxion Biosciences Inc - Product Pipeline Analysis, [..]
Summary Fluxion Biosciences Inc (Fluxion) is a provider of analytical and live cell analysis tools. The company's products include [..]
 
More From Health
Invacare International take powerchairs to a new [..]
Touch screen remote Introducing next generation technology to powerchairs, Invacare is pleased to present the REM400 remote with [..]
Award Winning Ambient Noise App TaoMix 2 [..]
MONTREAL, CANADA – August 16, 2017 – Available today on Google Play, TaoMix 2 makes it easy for anyone to [..]
Riverside Clinic FB Source of Inspiring Articles [..]
Riverside Clinic is an addiction treatment service for individuals suffering due to substance abuse disorders. The Melbourne-based centre [..]
Singapore eDevelopment Biomedical Subsidiary Partners Chemia [..]
SINGAPORE, Aug 15, 2017 - (ACN Newswire) - Singapore Exchange Catalist-listed Singapore eDevelopment Limited ("SeD") announced [..]
Experience the Benefits of Croton Essential Oils [..]
New Delhi, Friday, August 11, 2017: Essential Oils are one of the most popular natural products that people all over [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.